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Abstract
Background: In the HPV FOCAL trial, we will establish the efficacy of hr-HPV DNA testing as a stand-alone
screening test followed by liquid based cytology (LBC) triage of hr-HPV-positive women compared to LBC followed
by hr-HPV triage with ≥ CIN3 as the outcome.
Methods/Design: HPV-FOCAL is a randomized, controlled, three-armed study over a four year period conducted in
British Columbia. It will recruit 33,000 women aged 25-65 through the province’s population based cervical cancer
screening program. Control arm: LBC at entry and two years, and combined LBC and hr-HPV at four years among
those with initial negative results and hr-HPV triage of ASCUS cases; Two Year Safety Check arm: hr-HPV at entry
and LBC at two years in those with initial negative results with LBC triage of hr-HPV positives; Four Year Intervention
Arm: hr-HPV at entry and combined hr-HPV and LBC at four years among those with initial negative results with
LBC triage of hr-HPV positive cases
Discussion: To date, 6150 participants have a completed sample and epidemiologic questionnaire. Of the 2019
women enrolled in the control arm, 1908 (94.5%) were cytology negative. Women aged 25-29 had the highest
rates of HSIL (1.4%). In the safety arm 92.2% of women were hr-HPV negative, with the highest rate of hr-HPV
positivity found in 25-29 year old women (23.5%). Similar results were obtained in the intervention arm HPV FOCAL
is the first randomized trial in North America to examine hr-HPV testing as the primary screen for cervical cancer
within a population-based cervical cancer screening program.
Trial Registration: International Standard Randomised Controlled Trial Number Register, ISRCTN79347302
Background
Cervical cancer screening using cervical cytology (the
Pap smear) has been an extremely successful public
health intervention, achieving reductions in cervical can-
cer incidence of up to 80% where practiced effectively
[1]. However, the Pap smear was introduced over 50
years ago and studies have now proven it has significant
limitations. Data from some jurisdictions indicate that
cervical cancer rates have reached a nadir, and meta-
analyses indicate that the sensitivity of a single Pap test
to detect cervical intraepithelial neoplasia (CIN) or inva-
sive cervical cancer is less than 60% [2,3].
There is now ample evidence that infection with high-
risk types of the Human Papillomavirus (hr-HPV) is a
requisite intermediate step for the development of cervi-
cal cancer and its precursors [4,5]. On this basis, it has
been proposed that testing for the presence of hr-HPV
could improve cervical cancer screening. HPV testing is
recommended for follow up of abnormal cytology in
women over the age of 30 and for the surveillance of
patients after colposcopic treatment for CIN [6]. When
* Correspondence: gina.ogilvie@bccdc.ca
1Department of Family Practice, University of British Columbia, Vancouver,
Canada
Ogilvie et al. BMC Cancer 2010, 10:111
http://www.biomedcentral.com/1471-2407/10/111
© 2010 Ogilvie et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.used as a primary screening tool in cross sectional stu-
dies, it has been demonstrated that hr-HPV testing has
a higher sensitivity and negative predictive value (NPV)
f o rC I N 2o rw o r s e( ≥ CIN2) detection than either the
conventional Pap smear or liquid based cytology (LBC),
albeit with a lower specificity and positive predictive
value (PPV) [7-12]. In recognition of this, one approach
for screening would be to use hr-HPV testing as a sin-
gle primary screening test with cytology reserved only
for the triage of women having a positive test, especially
following the advent of HPV vaccination [12,13]. This
would offer several advantages over combined testing:
￿ Screening would be undertaken with the test hav-
ing higher sensitivity (hr-HPV testing);
￿ 85-90% of women would be returned immediately
t or o u t i n es c r e e n i n gw i t han e g a t i v eh r - H P Vt e s t
without incurring the cost of cytology, which would
be reserved only for those with a positive hr-HPV;
￿ The high-volume screening of samples would be
undertaken with a non-subjective test that can be
automated, while the subjective, labour-intensive test
would be restricted to high-risk samples that could
be examined with greater vigilance because of the
reduced number to be interpreted;
￿ It represents a more robust screening approach
that could serve the additional purpose of post-vac-
cination surveillance in the population [13];
￿ The recommended cervical cancer screening inter-
val can be extended, as the long term risk of CIN3
or worse in women with a negative hr-HPV test is
much lower than those who have a negative cytol-
ogy, thus providing greater reassurance to women
and also resulting in potential cost savings [10].
To examine these concepts, several international large
randomized controlled trials (RCT) are being conducted
in Europe and in Canada to evaluate HPV testing as
part of primary cervical cancer screening [9,14-21].
With the exception of the Finnish Randomized Public
Health Trial and phase 2 of the New Technologies for
Cervical Cancer Screening (NTCC) trial in Italy, these
trials have compared combined HPV and cytology test-
ing vs. cytology alone as the primary screening interven-
tion. The Phase 2 of NTCC and the Finnish trials are
comparing HPV versus cytology as the primary screen,
and both of these employ conventional cytology as
opposed to liquid based cytology (LBC) which is repla-
cing conventional cytology in several jurisdictions
[14,20]. To date, there has not been a RCT of hr-HPV
detection followed by cytology triage of hr-HPV positive
women, compared to cytology alone in a population
based screening program in North America, and no
trials have utilized LBC. It is essential to properly
evaluate this approach within the context of a popula-
tion based cervical cancer screening program which
would provide generalizable evidence to inform policy
decisions concerning cervical cancer screening
internationally.
This paper describes the design and preliminary
screening results of the HPV FOCAL Trial. The primary
objective of the HPV FOCAL trial is to establish the
efficacy of hr-HPV testing followed by liquid based
cytology (LBC) triage of hr-HPV-positive women com-
pared to LBC followed by hr-HPV triage for cervical
cancer screening with ≥ CIN3 as the outcome, through
a comparison of the estimated decreases in cervical
intraepithelial neoplasia (CIN 2/3) that can be achieved
by each screening modality in successive screening
rounds. The secondary objectives of this trial are to
establish the appropriate screening interval for hr-HPV
negative women, using the current standard of a 2-year
recall interval for cytology negative women as the
benchmark of acceptable risk in British Columbia; to
establish the appropriate clinical follow-up for hr-HPV
positive women; and to establish the cost-effectiveness
of hr-HPV testing for primary screening, all within the
context of a population based Canadian cervical cancer
screening program. The results of this trial will demon-
strate whether or not the use of hr-HPV testing as a sin-
gle primary screening test within a population based
cervical cancer screening program will be able to pro-
vide further reductions in the incidence of cervical can-
cer and its precursor lesions, allow the screening
interval to be extended, and improve the cost-effective-
ness of cervical cancer screening.
Methods/Design
Trial Design
HPV FOCAL is a three-armed, RCT over a four year
period (Figure 1).
Control arm: LBC at entry and again at two years;
ASCUS cases are triaged with hr-HPV testing; combined
LBC and hr-HPV at four years (exit screen) among
those with initial negative results.
Two Year Safety Check arm:h r - H P Va te n t r y ;L B C
at two years (exit screen) in those with initial negative
hr-HPV results with LBC triage of hr-HPV positives at
either round.
Four Year Intervention Arm: hr-HPV at entry with
LBC triage of hr-HPV positives; combined hr-HPV and
LBC at four years (exit screen) among those with initial
hr-HPV negative results.
British Columbia Population Based Cervical Cancer
Screening Program
Since the 1960s, cervical cancer screening in British
Columbia has been organized as a centrally
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tory (Provincial Health Services Laboratories) processes
and interprets Pap test samples from all clinicians in the
province. A unified set of recommendations for the
management of women with abnormal Pap tests is pro-
duced by the British Columbia Cancer Agency (BCCA),
and is communicated to the healthcare providers with
the Pap test results. BCCA also manages a coordinated
follow-up system involving regional colposcopy clinics
across the province for women with abnormal Pap tests.
BCCA’s Cervical Cancer Screening Program maintains a
single data structure linking all Pap test results and dis-
ease outcomes, and provides overall program adminis-
tration and coordination of promotion, recruitment,
follow-up reminder system, follow-up tracking, quality
management, program evaluation and research support.
Study Population and Recruitment
Women aged 25 to 65, registered with Medical Services
Plan in British Columbia, who receive care from a
participating family physician (FP) for routine cervical
screening are eligible. Exclusion criteria are: a history of
histologically proven CIN2 or worse requiring treatment
in the last five years; a history of histologically proven
invasive cervical cancer; a Pap smear within the preced-
ing twelve months; no cervix; pregnant at time of enrol-
ment; HIV positive or on immunosuppressive
treatments; or unwilling or unable to provide informed
consent.
Women are invited to participate in the study when
they present for cervical cancer screening and are
deemed eligible to participate by their FP or when pre-
identified as being due for screening from the BCCA
centralized provincial cytology database. For the pre-
identified, the FP office sends the woman a study pack-
age that includes an invitation letter, a study informa-
tion pamphlet and the informed consent form. The
invitation letter requests women to phone their FP to
make an appointment for their cervical screening test
and also provides them with the opportunity to contact,
Figure 1 HPV FOCAL: a three-armed, RCT over a four year period.
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trial and decide on participation. All participants are
consented by their FP and are asked to complete an epi-
demiologic questionnaire. A financial implications ques-
t i o n n a i r ei sa l s oc o m p l e t e db yar a n d o ms a m p l eo f
participants. Full cervical cancer screening history is
available through data linkage to the cervical cancer
screening program, and HPV vaccination status is self
reported.
Study Protocol (Figure 1)
In addition to the control arm and the intervention arm,
a ‘two year safety-check’ arm is included in this trial. At
t h et i m eo ft h et r i a ld e s i g n ,t h e r ew e r ee t h i c a lc o n c e r n s
identified in changing the screening interval at the same
time as changing the primary screening tool in a clinical
trial. To that end, we included a safety check arm, to
examine the safety of hr-HPV testing within the usual
screening interval. This information will be used by the
data safety monitoring board to verify the safety of hr-
HPV testing at the two year interval and infer the suit-
ability of the intervention arm as the trial proceeds.
Two samples are collected during the initial screening
appointment. Specimen1 (LBC) is collected first with
the ThinPrep® Broom-like collection device and is
placed in a ThinPrep® PreservCyt vial (Hologic Inc, Bed-
ford MA) and is used for all the HPV FOCAL trial test-
ing. Specimen 2 is collected in Digene STM® (Qiagen,
Mississauga ON) and is frozen for future use. Both spe-
cimens are sent to the central laboratory in Vancouver,
for trial testing (specimen 1) and for storage (specimen
2). Upon sample receipt, the woman is randomized to
one of the three study arms and specimen 1 is aliquoted
(Figure 1). For those allocated to hr-HPV testing arms,
an aliquot is removed and processed using the Qiagen
sample conversion kit, and tested using the Digene
Hybrid Capture 2 (HC2) assay (Qiagen, Mississauga
ON), which tests simultaneously for the presence of
DNA from 13 hr-HPV types. Results are classified as hr-
HPV negative, hr-HPV positive or unsatisfactory. LBC
testing is conducted on specimen 1 using the ThinPrep®
collected device, according to the manufacturer’s recom-
mendations. Cytological evaluation and reporting follow
the Bethesda classification system [23].
Colposcopy
If the woman’s test results indicate that a colposcopy
referral is recommended (Figure 1), this will be con-
veyed to the FP with the study sample results. All colpo-
scopy examinations are performed at study-designated
colposcopy clinics in Vancouver and Victoria to ensure
consistency in diagnostic performance. Colposcopic
examinations performed in British Columbia are highly
standardized, and clinicians providing colposcopy adhere
to a study-agreed protocol.
Women referred for colposcopy fall into the following
major groupings:
a) Cytology: AGC (hr-HPV positive or not done);
b) Cytology: ASC-H or ≥ LSIL (hr-HPV positive or
not done);
c) Cytology: ASC-US; (hr-HPV positive or persistent
ASC-US which was initially hr-HPV negative).
Women are managed according to the standard pro-
vincial guidelines in the province of British Columbia
[24]. Colposcopy is used to assess the highest grade
lesion seen on the cervix and directed biopsy(s) is per-
formed as well as an endocervical curettage when
appropriate. The standard treatment for CIN2+ in Brit-
ish Columbia is an excisional treatment, most com-
monly loop electrosurgical excision procedure (LEEP)
and occasionally cone biopsy
Histology
Pathological interpretation of biopsies is conducted at
two centres which provide services to the participating
colposcopy clinics. Pathologists are blinded to cytology
and hr-HPV result when interpreting the slides. Histol-
ogy results are stored in the same Laboratory Informa-
tion System (LIS) as the cytology results.
Following standard practice, if there is significant dis-
cordance between the cytologic and histologic evalua-
tion which would potentially influence patient
management, the colposcopist contacts the laboratory to
request review and correlation of the histology and
cytology in order to resolve the discrepancy (e.g. a case
where HSIL cytology is noted, but negative histology,)
and determine an appropriate disease management
strategy.
A review of exit screen histology is an essential com-
ponent of the trial. Approximately 50% of exit screen
histology results will undergo second review by senior
study pathologists. If the primary and review histology
results agree, this will be the final study diagnosis, but
in the case of disagreement between primary and review
histology, the slide will be referred to another senior
pathologist. If this result agrees with either the primary
result or first review the agreed results will be the final
study diagnosis. If all 3 results are different, the final
study diagnosis will be established by consensus between
all three pathologists.
Randomization and Blinding
A database has been developed specifically for the HPV
FOCAL trial. Randomization occurs through this data-
base when samples are received at the laboratory. At the
time of randomization a Study Identification Number
(SIN) is allocated to the participant. Samples are strati-
fied by age and simple equal (1/3 probability) random
allocation occurs at the laboratory. Upon randomization,
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cessing (hr-HPV or LBC).
FPs and participants are blinded to study arm alloca-
tion. Participant results are communicated from the
BCCA to the FP office as soon as they are known. If the
participant’s initial screening results (hr-HPV or cytology)
are “negative” the report states “within normal limits”.
The report also states that the recommended follow-up
for that participant will be communicated to the FP in
two years’ time. This ensures blinding is maintained for
as long as possible and prevents any bias that may poten-
tially occur from knowledge of negative results. If the
screening results are hr-HPV and/or cytology positive,
the results are communicated from the BCCA to the FP
along with the recommended follow-up.
Statistical Considerations
Sample Size
The planned intake sample size is 11,000 women per
arm (33,000 total). Power calculations were performed
using the nQuery Advisor, version 2, software package.
Rates of hr-HPV infection and associated histologically
proven disease were based on results from the HART
study [9], prevalence rates from the CCCaST trial con-
ducted in Quebec and Newfoundland [8,25]. Sample
sizes were based on requiring at least an 80% power to
detect relative differences (alternative hypothesis) of 20%
in the outcome comparisons for intervention versus
control at four years and control versus safety check
arms at two years.
Analysis
Primary Outcome Measures
￿ Control and intervention arms: Cumulative inci-
dent ≥ CIN3 detected up to and including four years
in both the control arm and the intervention arm
￿ Control and safety check arms: Incident ≥ CIN2
detected at two years. If the number of ≥ CIN2 in
the safety-check group exceeds 0.8 times that in the
control arm at the 2 year screen, then the trial will
conclude and women in the four year intervention
arm will be recalled at two years for their exit
screen.
Secondary Outcome Measures
￿ Rates of ≥ CIN2 and hr-HPV respectively at initial
screen in control and safety/intervention arms;
￿ Rates of incident ≥ CIN2 at two years in control
arm and at four years in intervention arm;
￿ The total estimated cost per woman screened and
the total estimated cost per quality-adjusted life-year
gained for each technology;
￿ Clearance of hr-HPV infection in women who are
hr-HPV-positive and cytology negative at initial
screen.
The primary outcome analysis will be a comparison of
histologically confirmed ≥ CIN3 between the interven-
tion and control arms. Rates of lesion occurrence will
be calculated using person-time denominators for the
different study intervals and compared via Kaplan-Meier
plots [26]. Rates will be calculated for specific age
groups within the study. Significance testing will be
based on Poisson statistics and performed at the 5%
level (2-sided). Analysis will also be performed using
logistic regression to permit control of potential con-
founding factors since for some comparisons balance
may not be assured by randomization. The primary
comparison of disease rates between test negative
groups (at entry screen) will not control for potential
confounding factors since they are not balanced by ran-
domization and the tests may select for different charac-
teristics. Covariate-adjusted analyses will be performed
to determine the extent to which any difference is
explicable by potential confounders (e.g., age and sexual
behaviour).
Ethical Issues
This study is being conducted in accordance with the
Ethical Conduct for Research Involving Humans Tri-
Council Policy Statement http://www.nserc-crsng.gc.ca/
NSERC-CRSNG/governance-gouvernance/ethics-ethi-
ques_eng.asp. Ethics approval has been obtained from
appropriate local research ethics boards. The trial regis-
tration number is International Standard Randomised
Controlled Trial Number Register: ISRCTN79347302.
All information about this trial is kept behind locked
doors or in secure computer files. On interim and final
reports, all data will be de-identified.
Discussion
Preliminary Findings
Recruitment for trial participants commenced in
December 21, 2007 through 147 FP offices. As of
December 31, 2009, 37,347 women were identified as
potentially eligible through the Cervical Cancer Screen-
ing Program database. Of the above identified, 28,525
women were sent invitation letters from their family
physicians to participate in this study, 613 were ineligi-
ble and 2995 declined participation (data on non
responders not available). 9842 women were enrolled in
the trial through 147 FP clinics from Vancouver Island
and Metro Vancouver and 6150 had completed both the
epidemiology questionnaire (Epi-Q) and had a prelimin-
ary study specimen result. Data will be presented on
women who had both a study specimen result and com-
pleted Epi-Q.
Participant age ranged from 25 to 65 years, with a
median age of 45 (Table 1). As part of trial eligibility,
women do not have a history of invasive cancer and
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the last 5 years. The majority of women commenced
sexual intercourse prior to the age of 19 and over 90%
reported their sexual debut by the age of 24. Just over
sixty percent of women had never smoked (Table 2).
The distribution of study characteristics among trial
arms was well balanced.
Of the 2019 women enrolled in the control arm, 1908
(94.5%) were cytology negative. Sixteen women (0.8%)
had high grade squamous intraepithelial lesions (HSIL)
on their cytology evaluations, and women aged 25-29
had the highest rates of HSIL (1.4%) (Table 3). In the
safety arm 92.2% of women were hr-HPV negative. The
highest rate of hr-HPV positivity was in 25-29 year old
women (23.5%) and the lowest rate was found in
Table 1 Socio-demographic Characteristics of 6150 HPV FOCAL Participants by Study Arm
Arm
Control (%) Safety (%) Intervention (%) Total (%)
Age Group (years)
25-29 141 (7%) 153 (7.2%) 127 (6.3%) 421 (6.8%)
30-34 172 (8.5%) 172 (8.1%) 166 (8.3%) 510 (8.3%)
35-39 284 (14.1%) 315 (14.9%) 269 (13.4%) 868 (14.1%)
40-44 318 (15.8%) 351 (16.6%) 319 (15.9%) 988 (16.1%)
45-49 357 (17.7%) 371 (17.5%) 376 (18.7%) 1104 (18%)
50-54 309 (15.3%) 312 (14.7%) 283 (14.1%) 904 (14.7%)
55-59 252 (12.5%) 241 (11.4%) 279 (13.9%) 772 (12.6%)
60-65 186 (9.2%) 204 (9.6%) 193 (9.6%) 583 (9.5%)
Cultural Group
Aboriginal 61 (3%) 58 (2.7%) 48 (2.4%) 167 (2.7%)
Black 10 (0.5%) 10 (0.5%) 7 (0.3%) 27 (0.4%)
British 1113 (55.1%) 1178 (55.6%) 1118 (55.6%) 3409 (55.4%)
Chinese 181 (9%) 211 (10%) 198 (9.8%) 590 (9.6%)
French 196 (9.7%) 178 (8.4%) 174 (8.6%) 548 (8.9%)
Southeast Asian 9 (0.4%) 8 (0.4%) 4 (0.2%) 21 (0.3%)
Northern European 136 (6.7%) 144 (6.8%) 160 (8%) 440 (7.2%)
Southern European 135 (6.7%) 119 (5.6%) 97 (4.8%) 351 (5.7%)
Eastern European 251 (12.4%) 259 (12.2%) 243 (12.1%) 753 (12.2%)
Western European 316 (15.7%) 355 (16.8%) 335 (16.7%) 1006 (16.4%)
Other 316 (15.7%) 320 (15.1%) 282 (14%) 918 (14.9%)
Marital Status
Divorced 176 (8.8%) 209 (9.9%) 212 (10.6%) 597 (9.8%)
Married 1324 (66.3%) 1381 (65.7%) 1274 (64%) 3979 (65.3%)
Single 286 (14.3%) 292 (13.9%) 285 (14.3%) 863 (14.2%)
Widowed 30 (1.5%) 25 (1.2%) 25 (1.3%) 80 (1.3%)
Common-law 182 (9.1%) 195 (9.3%) 196 (9.8%) 573 (9.4%)
Educational History
Elementary/Incomplete High School 41 (2.1%) 55 (2.6%) 46 (2.3%) 142 (2.3%)
High School (complete) 296 (14.8%) 292 (14%) 283 (14.3%) 871 (14.3%)
Trade Certificate/College 591 (29.6%) 629 (30.1%) 608 (30.6%) 1828 (30.1%)
University (incomplete) 134 (6.7%) 121 (5.8%) 131 (6.6%) 386 (6.4%)
University graduate or higher 935 (46.8%) 991 (47.5%) 917 (46.2%) 2843 (46.8%)
Employment
Currently Working 1588 (78.8%) 1666 (78.8%) 1556 (77.7%) 4810 (78.5%)
On Disability 58 (2.9%) 61 (2.9%) 49 (2.5%) 168 (2.8%)
On Social Assistance 4 (0.2%) 7 (0.3%) 9 (0.5%) 20 (0.3%)
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in the intervention arm, where 92.1% were hr-HPV
negative and the highest rates of hr-HPV positivity
(24.4%) were found in women aged 25-29 (Table 4).
The HPV FOCAL study is the first RCT to examine
hr-HPV testing followed by LBC triage compared to
LBC followed by hr-HPV triage as the primary screen
for cervical cancer within the context of a population
based cervical cancer screening program in North
America. This study will provide generalizable evidence
to inform policy decisions concerning cervical cancer
screening internationally, particularly in settings where
LBC has already been adopted or is under consideration.
Participants are women who are part of a long
Table 2 Life style, Pregnancy and Sexual Characteristics of 6150 HPV FOCAL Participants by Study Arm
Arm
Control (%) Safety (%) Intervention (%) Total (%)
Smoked Regularly (Ever) 790 (41.3%) 746 (37.7%) 764 (40.4%) 2300 (39.8%)
Mean Age of Started Smoking in Years (N = 2300) 16.4 16.6 16.5 16.5
Current Smoker 150 (19.1%) 135 (18.2%) 144 (18.8%) 429 (18.7%)
History of Sexual Intercourse
Never sexually active 8 (0.4%) 9 (0.4%) 6 (0.3%) 23 (0.4%)
Mean Age of Sexual Debut in Years (N = 5984) 18.8 18.8 18.7 18.8
Lifetime No. Male Sexual Partners (N = 6013)
0 1 (0.1%) 4 (0.2%) 4 (0.2%) 9 (0.1%)
1 420 (21.2%) 429 (20.8%) 422 (21.4%) 1271 (21.1%)
2-5 650 (32.9%) 757 (36.6%) 685 (34.8%) 2092 (34.8%)
6-10 482 (24.4%) 458 (22.2%) 458 (23.3%) 1398 (23.2%)
11-50 391 (19.8%) 393 (19%) 376 (19.1%) 1160 (19.3%)
51-99 22 (1.1%) 23 (1.1%) 22 (1.1%) 67 (1.1%)
99+ 11 (0.6%) 3 (0.1%) 2 (0.1%) 16 (0.3%)
Male Sexual Partners in Past Six Months (N = 5990)
0 294 (14.9%) 322 (15.6%) 324 (16.6%) 940 (15.7%)
1 1618 (82.1%) 1681 (81.4%) 1586 (81.2%) 4885 (81.6%)
2+ 59 (3%) 62 (3%) 44 (2.3%) 165 (2.8%)
History of Pregnancy
Ever Pregnant before (N = 6004) 1588 (81.1%) 1654 (79.9%) 1602 (81.1%) 4844 (80.7%)
Mean age at first pregnancy (N = 4844) 26.5 26.5 26.3 26.5
Mean Number of Pregnancies (N = 4844) 2.7 2.6 2.7 2.7
Mean Age of Menarche (N = 6087) 12.8 12.9 12.8 12.8
Oral Contraceptive
Ever 1765 (87.4%) 1824 (86.1%) 1743 (86.6%) 5332 (86.7%)
Mean Years on Oral Contraceptives (N = 5332) 9.0 8.9 9.0 9.0
Contraception Method
Barrier (Ever) 1550 (76.8%) 1638 (77.3%) 1529 (76%) 4717 (76.7%)
Barrier (Current) 276 (13.7%) 293 (13.8%) 253 (12.6%) 822 (13.4%)
Vaginal (Ever) 197 (9.8%) 269 (12.7%) 243 (12.1%) 709 (11.5%)
Vaginal (Current) 7 (0.3%) 10 (0.5%) 11 (0.5%) 28 (0.5%)
Hormonal (Ever) 1771 (87.7%) 1829 (86.3%) 1746 (86.8%) 5346 (86.9%)
Hormonal (Current) 286 (14.2%) 291 (13.7%) 268 (13.3%) 845 (13.7%)
Permanent (Ever) 659 (32.6%) 689 (32.5%) 654 (32.5%) 2002 (32.6%)
Permanent (Current) 576 (28.5%) 626 (29.5%) 556 (27.6%) 1758 (28.6%)
Rhythm/Withdrawal (Ever) 204 (10.1%) 222 (10.5%) 176 (8.7%) 602 (9.8%)
Rhythm/withdrawal (Current) 53 (2.6%) 54 (2.5%) 39 (1.9%) 146 (2.4%)
Duration of HRT for Menopause in Years (N = 241) 4.2 4.5 5.6 4.7
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sent a population based cohort of women at average risk
for cervical cancer in North America. Study characteris-
tics for the first 6,000 participants were well balanced
across the three trial arms. In each arm of the trial, over
90% of women were negative on their screening exami-
nation, with the majority of abnormalities found in
women in under the age of 35.
Important design elements in HPV FOCAL include
the use of LBC (a more universal cytology format in
North America) as opposed to conventional cytology;
the use of FPs as study collaborators to recruit partici-
pants; blinded analysis of cytology and pathology results
with respect to hr-HPV status; use of a single laboratory
for cytology analysis; inclusion of a two year safety arm
and standardized colposcopy protocols. The use of LBC
is of particular relevance because of the ability to use
the sample for reflex testing. LBC, which involves taking
a sample and placing it into a vial with liquid, and then
producing a slide for examination from a suspension of
the cells has been compared to conventional cytology in
many studies [27]. Studies have reported higher sensitiv-
ity with LBC compared to conventional smears, as well
as a greater proportion of adequate specimens for eva-
luation. However, there remains a divergence of opinion
on the advantages of LBC over conventional cytology,
and a recent RCT found that LBC had equivalent sensi-
tivity for ≥ CIN2 lesions relative to conventional Pap,
but had a lower rate of unsatisfactory smears when
compared with the latter [28]. In a cluster randomized
trial involving over 89,000 women, Siebers et al. [29]
found that LBC did not perform any better than well-
performed conventional Pap smears for the detection of
cervical cancer precursors. Despite the differences in
Table 3 Results of screening by Five Year Age Strata: Control (cytology) arm
Age
Strata
Cytology
Negative (%)
Cytology ASC-
US (%)
Cytology
ATY (%)
Cytology LSIL
(mild) (%)
Cytology
ASC-H (%)
Cytology
HSIL (%)
Cytology Smear
Unsatisfactory (%)
Total
25-29 123 (87.2) 4 (2.8) 0 (0.0) 6 (4.3) 2 (1.4) 2 (1.4) 4 (2.8) 141
30-34 157 (91.3) 1 (0.6) 1 (0.6) 9 (5.2) 0 (0.0) 2 (1.2) 2 (1.2) 172
35-39 270 (95.1) 6 (2.1) 0 (0.0) 5 (1.8) 1 (0.4) 1 (0.4) 1 (0.4) 284
40-44 302 (95.0) 3 (0.9) 1 (0.3) 6 (1.9) 0 (0.0) 3 (0.9) 3 (0.9) 318
45-49 336 (94.1) 9 (2.5) 0 (0.0) 5 (1.4) 1 (0.3) 4 (1.1) 2 (0.6) 357
50-54 296 (95.8) 4 (1.3) 0 (0.0) 2 (0.6) 2 (0.6) 2 (0.6) 2 (0.6) 309
55-59 244 (96.8) 0 (0.0) 0 (0.0) 3 (1.2) 0 (0.0) 0 (0.0) 5 (2.0) 252
60+ 180 (96.8) 1 (0.5) 1 (0.5) 0 (0.0) 1 (0.5) 2 (1.1) 1 (0.5) 186
Total 1908 (94.5) 28 (1.4) 4 (0.2) 36 (1.8) 7 (0.3) 16 (0.8) 20 (1.0) 2019
ASC-US - Atypical squamous cells of undetermined significance.
ATY - Atypical Glandular Cells/NOS; Atypical Endometrial Cells/NOS; Atypical Endocervical Cells/NOS
LSIL - Low-grade squamous intraepithelial lesion
ASC-H - Atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion.
HSIL - High-grade squamous intraepithelial lesion (moderate, severe dysplasia, Ca in situ).
Table 4 Results of screening by Five Year Age Strata: Safety Check and Intervention arms
Safety Check Arm Intervention Arm
Age
Strata
hr-HPV Negative
(%)
hr-HPV Positive
(%)
hr-HPV Unsatis
(%)
Total hr-HPV Negative
(%)
hr-HPV Positive
(%)
hr-HPV Unsatis
(%)
Total
25-29 117 (76.5) 36 (23.5) 0 (0.0) 153 95 (74.8) 31 (24.4) 1 (0.8) 127
30-34 151 (87.8) 21 (12.2) 0 (0.0) 172 146 (88.0) 20 (12.0) 0 (0.0) 166
35-39 284 (90.2) 31 (9.8) 0 (0.0) 315 239 (88.8) 30 (11.2) 0 (0.0) 269
40-44 324 (92.3) 26 (7.4) 1 (0.3) 351 300 (94.0) 18 (5.6) 1 (0.3) 319
45-49 358 (96.5) 13 (3.5) 0 (0.0) 371 354 (94.1) 19 (5.1) 3 (0.8) 376
50-54 293 (93.9) 18 (5.8) 1 (0.3) 312 267 (94.3) 15 (5.3) 1 (0.4) 283
55-59 232 (96.3) 9 (3.7) 0 (0.0) 241 265 (95.0) 13 (4.7) 1 (0.4) 279
60+ 195 (95.6) 9 (4.4) 0 (0.0) 204 188 (97.4) 4 (2.1) 1 (0.5) 193
Total 1954 (92.2) 163 (7.7) 2 (0.1) 2119 1854 (92.1) 150 (7.5) 8 (0.4) 2012
HPV Digene Negative: Non-reactive for HPV High or Intermediate risk types.
HPV Digene Positive: Reactive for HPV High or Intermediate risk types.
HPV Digene Unsatis: Results unsatisfactory - need to repeat specimen
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Page 8 of 10results, LBC has been widely adopted worldwide and
particularly in North America as a part of cervical can-
cer screening programs due to opportunities for auto-
mation, improved costs and single specimen collection
for HPV and other molecular tests. The HPV FOCAL
trial is well positioned to examine the contribution of
LBC with respect to primary HPV testing and inform
the discussion internationally. These findings would be
directly relevant to cervical cancer screening programs
worldwide as they consider the respective roles of LBC
and HPV testing in their future program delivery.
Findings from this preliminary analysis contribute to
available literature on the prevalence of HPV in Cana-
dian women. In this study of women recruited from a
population based screening program, eight percent were
positive for hr-HPV, with the highest prevalence rates
being found in women aged 25-29. In the first Canadian
study comparing Pap screening with hr-HPV screening,
women aged 30-69 from Newfoundland and Quebec
presenting for routine cervical cancer screening found
to have an hr-HPV prevalence of 6.1% overall [8,19,25].
In another study of hr-HPV prevalence in women in the
cervical cancer screening program in British Columbia,
Moore et al., using GP5+/GP6+ L1 consensus primers,
found a much higher hr-HPV prevalence of 13.9% [30].
Differences between Moore’s study and this study may
be attributed to differing recruitment methods (popula-
tion- vs. clinic-based) and different laboratory methods
for establishing presence or absence of hr-HPV. Further
afield, hr-HPV prevalence has ranged from 2.2% to
15.7% in several European studies of women attending
routine cervical screening [31]. As with this study, the
peak prevalence for hr-HPV is overall was found in
women between the ages of 25 and 34.
In a recent joint analysis of several European cohort
studies and clinical trials, Dillner found that hr-HPV
results had a high negative predictive value (99%), with
women who were negative for hr-HPV having a very
low risk of development of ≥ CIN3 in the next six years
[10]. This study concludes that this low six year cumula-
tive incidence rate for ≥ CIN3 among hr-HPV negative
women suggests that cervical cancer screening intervals
could be safely extended. In HPV FOCAL, by using a
safety check arm of two years, we will be able to exam-
ine in a controlled setting whether screening programs
can safely extend screening intervals from the traditional
o n eo rt w oy e a r su s e da r o u n dt h ew o r l d ,a n dc o n f i r m
the recommendations of the European consortium
study.
Data from ongoing randomized trials comparing pri-
mary screening for cervical cancer with HPV and cytol-
ogy have found that HPV-based screening offers
improved sensitivity for high grade CIN lesions, but
with a commensurate loss in specificity. In Dillner’s
review [10], he noted that most cohort studies and ran-
domized trials were limited by the number of ≥ CIN3
cases in the studies, thus reducing the statistical power
to examine the screening interval using ≥ CIN3 as the
endpoint. In this study, sample size calculations were
conducted with ≥ CIN3 as the endpoint, resulting in the
v e r yl a r g es a m p l es i z e( o v e r3 0 , 0 0 0w o m e n )w i t ht h e
intention of having enough power to compare the inci-
dent rates of ≥ CIN3 in the control arm compared to
the intervention arm. The expectation is that eventual
findings of the HPV FOCAL trial will contribute to the
growing body of literature examining the rapidly shifting
paradigm of cervical cancer screening in the era of
HPV-based technologies.
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